Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that v::RET status confers therapeutic sensitivity to Pralsetinib in patients with Non-Small Cell Lung Cancer.
The U.S. Food and Drug Administration granted approval to pralsetinib for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as detected by an FDA approved test (NSCLC).
This statement is based on a regulatory approval from the Food and Drug Administration:
GAVRETO is a kinase inhibitor indicated for treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer as detected by an FDA approved test (NSCLC).